Veracyte Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Veracyte Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- VCYT
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001384101
Board of directors
-
Bonnie H. Anderson · DirectorSince 2023
-
David Brent Shafer · DirectorSince 2024
-
Eliav Barr · DirectorSince 2023
-
Evan/ Fa Jones · DirectorSince 2023
-
Jens Holstein · DirectorSince 2023
-
John L. Bishop · DirectorSince 2023
-
Karin Eastham · DirectorSince 2023
-
Marc Stapley · Director · Chief Executive OfficerSince 2023
-
Muna Bhanji · DirectorSince 2023
-
Robert S. Epstein · DirectorSince 2023
-
Thomas F. Miller · DirectorSince 2024
Chief executives
Marc Stapley
· Chief Executive Officer
Dates unknown
Board connections
6 of this board's directors also sit on 11 other boards.
- via Muna Bhanji
- via David Brent Shafer
- via Bonnie H. Anderson
- via Muna Bhanji
- via Robert S. Epstein
- via Karin Eastham
- via Marc Stapley
- via Robert S. Epstein
- via Muna Bhanji
- via Karin Eastham
- via David Brent Shafer
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $22,244,657
- 61 sales by 11 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 21, 2026 | Leite John Officer (Global Chief Commercial Off) | Open-market sale | −4,015 | $40.00 | $160,600 |
| Sep 14, 2026 | Jens Holstein Director | Open-market sale | −5,000 | $40.95 | $204,747 |
| Sep 4, 2026 | Rebecca Chambers Officer (Chief Financial Officer) | Open-market sale | −2,477 | $42.81 | $106,030 |
| Sep 4, 2026 | Febbo Phillip G. Officer (Chief Scientific & Med Officer) | Open-market sale | −10,405 | $42.89 | $446,305 |
| Sep 4, 2026 | McGuire Annie Officer (EVP, General Counsel) | Open-market sale | −2,154 | $42.79 | $92,173 |
| Sep 4, 2026 | Rebecca Chambers Officer (Chief Financial Officer) | Open-market sale | −1,175 | $43.71 | $51,364 |
| Sep 4, 2026 | Febbo Phillip G. Officer (Chief Scientific & Med Officer) | Open-market sale | −2,705 | $43.66 | $118,105 |
| Sep 4, 2026 | McGuire Annie Officer (EVP, General Counsel) | Open-market sale | −1,100 | $43.67 | $48,039 |
| Sep 2, 2026 | Rebecca Chambers Officer (Chief Financial Officer) | Shares withheld for tax | −3,603 | $44.88 | $161,703 |
| Sep 2, 2026 | Febbo Phillip G. Officer (Chief Scientific & Med Officer) | Shares withheld for tax | −3,639 | $44.88 | $163,318 |
| Sep 2, 2026 | Leite John Officer (Global Chief Commercial Off) | Shares withheld for tax | −3,961 | $44.88 | $177,770 |
| Sep 2, 2026 | McGuire Annie Officer (EVP, General Counsel) | Shares withheld for tax | −3,215 | $44.88 | $144,289 |
| Sep 2, 2026 | Marc Stapley Director, Officer (Chief Executive Officer) | Shares withheld for tax | −8,782 | $44.88 | $394,136 |
| Sep 2, 2026 | Wygant Jonathan Officer (VP, Chief Accounting Officer) | Shares withheld for tax | −1,361 | $44.88 | $61,082 |
| Sep 1, 2026 | Muna Bhanji Director | Open-market sale | −1,864 | $42.97 | $80,096 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.